Payment overview · 2025
General Payments
$13,423.03
162 reported records · 27 companies
Healthcare provider profile · identity verified
Frank A Mcgrew, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MEMPHIS, TN · NPI 1922190396
Verified facts
What the public records show
CMS Open Payments records show Frank A Mcgrew, MD received $13,423.03 in general payments during 2025 across 162 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 55.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Ozempic, Verquvo, Wainua, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WAINUA as an associated drug or biological on 13293 records involving 7069 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wainua by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 586 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 417 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $7,468.26 | 55.6% | 12 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$2,541.12 | 18.9% | 17 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $524.25 | 3.9% | 23 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $357.44 | 2.7% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $302.14 | 2.2% | 10 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $247.56 | 1.8% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $207.95 | 1.6% | 5 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $193.79 | 1.4% | 8 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $185.07 | 1.4% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.65 | 1.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $147.76 | 1.1% | 8 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $144.01 | 1.1% | 1 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $143.34 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $141.25 | 1.1% | 5 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $135.31 | 1.0% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $114.13 | 0.8% | 5 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $61.08 | 0.5% | 2 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $56.97 | 0.4% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $49.36 | 0.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $49.12 | 0.4% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $43.83 | 0.3% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $26.75 | 0.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.94 | 0.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.58 | 0.2% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $21.72 | 0.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.87 | 0.1% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.78 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,301.53 | 154 |
| Consulting Fee | $4,620.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,500.00 | 1 |
| Travel and Lodging | $937.51 | 5 |
| Education | $63.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $2,739.93 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $524.25 | 23 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $357.44 | 20 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $302.14 | 10 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $262.83 | 3 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $185.07 | 8 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $175.28 | 7 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $170.23 | 7 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $166.28 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $147.76 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $146.21 | 6 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $144.01 | 1 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $144.01 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $144.01 | 1 | 2025 |
Source payment records
|
|||||
| PAMIRA Normalized: pamira |
Device | BIOTRONIK INC. | $144.01 | 1 | 2025 |
Source payment records
|
|||||
| Solia Normalized: solia |
Device | BIOTRONIK INC. | $144.01 | 1 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $143.34 | 1 | 2025 |
Source payment records
|
|||||
| EPI-EASE EPICARDIAL ACCESS SYSTEM Normalized: epi ease epicardial access system |
Device | AtriCure, Inc. | $135.31 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $117.30 | 4 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $114.13 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $91.88 | 4 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $81.28 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $61.08 | 2 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $56.97 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $49.36 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $49.12 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.50 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $43.83 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $43.82 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $42.07 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 586 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 156 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 148 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 66 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 216 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 42 | exact normalized | Medicare Part D |
| WAINUA wainua |
2025 | Wainua | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
156 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | WAINUA open payments reported associated product |
CMS Open Payments — General Payments 13293 supporting records · 7069 recipient NPIs · example record 1206131360 |
Wainua · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 45 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
586 | 127 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | 18 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
417 | 92 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
216 | 71 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 1369 | 392 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1248 | 371 |
| Atorvastatin Calcium | Atorvastatin Calcium | 816 | 232 |
| Metoprolol Succinate | Metoprolol Succinate | 679 | 186 |
| Amlodipine Besylate | Amlodipine Besylate | 658 | 198 |
| Losartan Potassium | Losartan Potassium | 637 | 189 |
| Eliquis | Apixaban | 586 | 127 |
| Clopidogrel | Clopidogrel Bisulfate | 512 | 142 |
| Amiodarone Hcl | Amiodarone Hcl | 492 | 138 |
| Carvedilol | Carvedilol | 479 | 138 |
| Doxazosin Mesylate | Doxazosin Mesylate | 450 | 113 |
| Entresto | Sacubitril/Valsartan | 417 | 92 |
| Repatha Sureclick | Evolocumab | 382 | 81 |
| Spironolactone | Spironolactone | 368 | 102 |
| Furosemide | Furosemide | 354 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 338 | 98 |
| Potassium Chloride | Potassium Chloride | 338 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 84 |
| Hydralazine Hcl | Hydralazine Hcl | 224 | 63 |
| Ozempic | Semaglutide | 216 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 59 |
| Lisinopril | Lisinopril | 190 | 58 |
| Xarelto | Rivaroxaban | 185 | 40 |
| Digoxin | Digoxin | 178 | 44 |
| Warfarin Sodium | Warfarin Sodium | 178 | 46 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 172 | 42 |
| Vascepa | Icosapent Ethyl | 158 | 49 |
| Farxiga | Dapagliflozin Propanediol | 156 | 31 |
| Ranolazine Er | Ranolazine | 150 | 34 |
| Jardiance | Empagliflozin | 148 | 45 |
| Nexletol | Bempedoic Acid | 113 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 96 | 34 |
| Icosapent Ethyl | Icosapent Ethyl | 93 | 34 |
| Ramipril | Ramipril | 91 | 27 |
| Flecainide Acetate | Flecainide Acetate | 90 | 23 |
| Sotalol | Sotalol Hcl | 90 | 20 |
| Allopurinol | Allopurinol | 84 | 26 |
| Prasugrel Hcl | Prasugrel Hcl | 83 | 20 |
| Simvastatin | Simvastatin | 78 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 23 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 71 | 26 |
| Midodrine Hcl | Midodrine Hcl | 70 | 19 |
| Chlorthalidone | Chlorthalidone | 67 | 19 |
| Praluent Pen | Alirocumab | 67 | suppressed |
| Kerendia | Finerenone | 66 | 18 |
| Colesevelam Hcl | Colesevelam Hcl | 63 | 19 |
| Benazepril Hcl | Benazepril Hcl | 62 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | 16 |
| Nitroglycerin | Nitroglycerin | 58 | 40 |
| Cilostazol | Cilostazol | 55 | 19 |
| Colestipol Hcl | Colestipol Hcl | 55 | 12 |
| Omeprazole | Omeprazole | 51 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 13 |
| Mounjaro | Tirzepatide | 48 | 18 |
| Multaq | Dronedarone Hcl | 46 | 13 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 45 | suppressed |
| Torsemide | Torsemide | 43 | 19 |
| Verquvo | Vericiguat | 42 | 11 |
| Vyndamax | Tafamidis | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 38 | suppressed |
| Metformin Hcl | Metformin Hcl | 34 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 34 | 19 |
| Propafenone Hcl | Propafenone Hcl | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 12 |
| Eplerenone | Eplerenone | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Captopril | Captopril | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Wegovy | Semaglutide | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 13 |
| Metolazone | Metolazone | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Droxidopa | Droxidopa | 15 | suppressed |
| Wainua | Eplontersen Sodium | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Corlanor | Ivabradine Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Letairis | Ambrisentan | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Orenitram Er | Treprostinil Diolamine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,423.03 · 162 records | E.R. Squibb & Sons, L.L.C. | AMVIA EDGE, AMVUTTRA, AURORA EV-ICD MRI SURESCAN, Acticor 7 VR-T DX, Attruby, BIOMONITOR, Barostim Neo System, CAMZYOS, CARDIOMEMS, CDS - MCT/CEM Monitoring, ELIQUIS, EPI-EASE EPICARDIAL ACCESS SYSTEM, FARXIGA, FFRct, FUROSCIX, INJECTAFER, INSPIRE, JARDIANCE, Kerendia, LEQVIO, LifeVest, OPSUMIT, OPSYNVI, Optimizer, Ozempic, PAMIRA, RECORLEV, REPATHA, RHYTHM EXPRESS, Solia, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, UPTRAVI, VERQUVO, Veozah, WAINUA, WINREVAIR, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error